Popular
CYTK · Medicine & biotech · U.S.

Cytokinetics

Makes medicines for diseases of the heart muscle.

Company Health

6
/100
Fragile
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $892 of every $100 in sales.
Is it growing?
6 of 25 · Poor
Sales shrank about 2% a year over the last 3 years.
Can it handle what it owes?
0 of 25 · Poor
Its business used cash last year, and it owes $146 of every $100 it owns.
Does it bring in spare cash?
0 of 25 · Poor
It spent more cash than it brought in: $607 of every $100 in sales.

Who owns it

1 of 23 own it · 1 sold some
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Cytokinetics’ yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $55.8 million in 2020 to $88.0 million in 2025, and it lost money every year.
2025
Sales
$88.0 million
Loss
$785 million

Spare cash each year

It spent more cash than it brought in every year: $535 million more in 2025.
2025
Cash shortfall
$535 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owed $2.08 billion, more than everything it owned ($1.42 billion).

Key facts

From its yearly report for 2025.
Sales
$88.0 million
Loss
$785 million
Cash shortfall
$535 million
Cash in the bank
$123 million
Everything it owes
$2.08 billion
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Feb 26, 2026
Figures from Cytokinetics’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy